Get to know our clinical trials

Clinical trial of ranibizumab in patients with neovascular age-related macular degeneration

THE PURPOSE OF THIS STUDY IS TO EVALUATE THE EFFECTS, GOOD OR BAD, OF RANIBIZUMAB ADMINISTERED THROUGH AN OCULAR IMPLANT (ALSO KNOWN AS A PORT DELIVERY SYSTEM WITH RANIBIZUMAB OR PDS DEVICE) IN PATIENTS WITH WET AMD. THE OCULAR IMPLANT DELIVERS RANIBIZUMAB CONTINUOUSLY (WITHOUT INTERRUPTION) OVER AN EXTENDED PERIOD OF TIME TO THE BACK OF THE EYE AND CAN BE RECHARGED BY THE STUDY PHYSICIAN. THE INTENTION IS TO KEEP THE IMPLANT IN THE EYE PERMANENTLY, UNLESS IT NEEDS TO BE REMOVED FOR MEDICAL REASONS.

Navarre headquarters
Madrid headquarters
Status
reclutamiento
headquarters
Pamplona

Technical Summary

  • PHASE IIIB, GLOBAL, MULTICENTER, RANDOMIZED, MULTICENTER, BLINDED TO VISUAL EVALUATOR, PHASE IIIB STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF RANIBIZUMAB ADMINISTERED WITH THE PORT DELIVERY SYSTEM DEVICE USING A 36-WEEKLY REFILL SCHEDULE IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (VELODROME)
  • Code EudraCT: 2020-001313-20
  • Protocol number: WR42221
  • Promoter: Roche Farma, S.A.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.